DE69631654D1 - Biodegradierbare polymermatrix mit verzögerter freisetzung von lokalanaesthetika und glucocorticoiden - Google Patents

Biodegradierbare polymermatrix mit verzögerter freisetzung von lokalanaesthetika und glucocorticoiden

Info

Publication number
DE69631654D1
DE69631654D1 DE69631654T DE69631654T DE69631654D1 DE 69631654 D1 DE69631654 D1 DE 69631654D1 DE 69631654 T DE69631654 T DE 69631654T DE 69631654 T DE69631654 T DE 69631654T DE 69631654 D1 DE69631654 D1 DE 69631654D1
Authority
DE
Germany
Prior art keywords
microspheres
biodegradable polymer
localanaesthetic
glucocorticoids
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631654T
Other languages
English (en)
Inventor
Charles B Berde
Robert S Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Application granted granted Critical
Publication of DE69631654D1 publication Critical patent/DE69631654D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
DE69631654T 1995-05-01 1996-05-01 Biodegradierbare polymermatrix mit verzögerter freisetzung von lokalanaesthetika und glucocorticoiden Expired - Lifetime DE69631654D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/432,402 US5700485A (en) 1992-09-10 1995-05-01 Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
PCT/US1996/006085 WO1996034599A1 (en) 1995-05-01 1996-05-01 Prolonged nerve blockage by the combination of local anesthetics and glucocorticoids

Publications (1)

Publication Number Publication Date
DE69631654D1 true DE69631654D1 (de) 2004-04-01

Family

ID=23716012

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631654T Expired - Lifetime DE69631654D1 (de) 1995-05-01 1996-05-01 Biodegradierbare polymermatrix mit verzögerter freisetzung von lokalanaesthetika und glucocorticoiden

Country Status (8)

Country Link
US (2) US5700485A (de)
EP (1) EP0825853B1 (de)
JP (1) JPH11504634A (de)
AT (1) ATE260095T1 (de)
AU (1) AU705737B2 (de)
CA (1) CA2220180A1 (de)
DE (1) DE69631654D1 (de)
WO (1) WO1996034599A1 (de)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
ATE267587T1 (de) * 1995-06-09 2004-06-15 Euro Celtique Sa Formulierungen und verfahren für eine verlängerte lokalanästhesie
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
WO1997032606A1 (en) * 1996-03-05 1997-09-12 Robert Gurny Pharmaceutical compositions containing buffered ortho ester polymers
JPH11511763A (ja) 1996-06-24 1999-10-12 ユーロ―セルティーク，エス．エイ． 安全な局所麻酔の提供方法
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
ES2130969B1 (es) * 1997-02-24 2000-02-16 Univ Valencia Estudi General Biomembranas para la encapsulacion extemporanea de tetracaina.
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
BR9815499A (pt) 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
ES2359973T3 (es) 1998-03-19 2011-05-30 MERCK SHARP & DOHME CORP. Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
US6451335B1 (en) 1998-07-02 2002-09-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
US6325788B1 (en) 1998-09-16 2001-12-04 Mckay Douglas William Treatment of wound or joint for relief of pain and promotion of healing
CA2358296A1 (en) * 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
PT1163019E (pt) * 1999-03-25 2007-12-06 Metabolix Inc Dispositivos médicos e aplicações de polímeros de poli-hidroxialcanoato
WO2001008717A1 (en) * 1999-08-03 2001-02-08 Smith & Nephew, Inc. Controlled release implantable devices
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
US20060269602A1 (en) * 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US8403954B2 (en) 2001-05-22 2013-03-26 Sanostec Corp. Nasal congestion, obstruction relief, and drug delivery
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1703197A (zh) * 2001-11-14 2005-11-30 阿尔扎有限公司 可注射的长效组合物和其使用
MXPA04004665A (es) 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
CN1638734A (zh) * 2002-02-22 2005-07-13 参天制药株式会社 微粒结膜下给药的药物释放系统
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8150520B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods for catheter-based renal denervation
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US20040006052A1 (en) * 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
NZ537955A (en) 2002-07-31 2007-10-26 Alza Corp Injectable depot compositions and uses thereof
CN101057824A (zh) 2002-07-31 2007-10-24 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
NZ539166A (en) * 2002-09-05 2008-03-28 Univ Wm Marsh Rice A controlled release device comprising antibiotic microspheres for treatment of infections and osteomyelitis
US8986737B2 (en) * 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
WO2004034975A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Sustained release profile modification
WO2004035762A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US7144427B2 (en) 2002-12-05 2006-12-05 Depuy Products, Inc. Apparatus and method for advancing synovial fluid in a prosthetic joint
JP2006523613A (ja) 2002-12-20 2006-10-19 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ 徐放性医薬投与のための被覆粒子
US9445901B2 (en) * 2003-03-12 2016-09-20 Deger C. Tunc Prosthesis with sustained release analgesic
EP2860292B1 (de) 2003-05-08 2020-07-22 Tepha, Inc. Medizinische Polyhydroxyalkanoattextilien und -fasern
CA2527994C (en) * 2003-06-03 2014-11-18 Santen Pharmaceutical Co., Ltd. Process for producing microparticles
EP1638530A2 (de) * 2003-06-20 2006-03-29 Royer Biomedical, INC. Arzneimittel-polymer-komplexe
CA2531833C (en) * 2003-07-08 2009-10-20 Tepha, Inc. Poly-4-hydroxybutyrate matrices for sustained drug delivery
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
WO2005020825A1 (en) * 2003-08-22 2005-03-10 Tepha, Inc. Polyhydroxyalkanoate nerve regeneration devices
WO2005070333A1 (en) * 2004-01-13 2005-08-04 Orthobiologica, Inc. Drug delivery to a joint
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
EP1758633B1 (de) * 2004-05-13 2015-03-18 Medtronic Vascular, Inc. Verfahren für das compoundieren eines therapeutikums an die adventitia eines gefässes
EP3417895A1 (de) 2004-07-28 2018-12-26 Medtronic Ardian Luxembourg S.à.r.l. Verfahren und vorrichtungen für die nierennervenblockade
EP1778305B1 (de) * 2004-08-03 2010-07-07 Tepha, Inc. Nichtkräuselnde polyhydroxyalkanoatnähte
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1845951B1 (de) * 2005-01-28 2010-09-15 Tepha, Inc. Embolisierung unter verwendung von poly-4-hydroxybutyrat-partikeln
CN1291754C (zh) 2005-07-12 2006-12-27 李赴朝 局麻药增效延时剂
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
JP5334588B2 (ja) 2005-11-28 2013-11-06 マリナス ファーマシューティカルズ ガナキソロン製剤、およびその作製方法、およびその使用
WO2007090897A1 (en) * 2006-02-10 2007-08-16 Biocompatibles Uk Limited Loading of hydrophobic drugs into hydrophilic polymer delivery systems
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
WO2008005371A2 (en) * 2006-06-29 2008-01-10 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
WO2008039995A2 (en) * 2006-09-28 2008-04-03 Vance Products Incorporated, D/Ba Cook Urological Incorporated Medical device including a bioactive in a non-ionic and an ionic form and methods of preparation thereof
US20080081829A1 (en) * 2006-09-28 2008-04-03 Med Institute, Inc Medical Device Including an Anesthetic and Method of Preparation Thereof
WO2008042228A2 (en) * 2006-09-28 2008-04-10 Med Institute, Inc. Medical devices incorporating a bioactive and methods of preparing such devices
US7943683B2 (en) 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
EP2144599B1 (de) 2007-03-02 2010-08-04 Farnam Companies, Inc. Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
EP2200607A4 (de) 2007-09-10 2012-02-22 Calcimedica Inc Verbindungen als modulatoren von intrazellulärem calcium
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
WO2009143174A2 (en) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Chemical permeation enhancers enhance nerve blockade by toxins
AU2009270695A1 (en) 2008-07-17 2010-01-21 Ap Pharma Methods for enhancing the stability of polyorthoesters and their formulations
BRPI0917719A2 (pt) 2008-08-27 2019-11-19 Calcimedica Inc compostos que modulam cálcio intracelular
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20100203102A1 (en) * 2009-02-10 2010-08-12 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using bupivacaine and an anti-onflammatory agent
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
WO2011017520A1 (en) 2009-08-05 2011-02-10 Wake Forest University Health Sciences Compositions and methods for inducing apoptosis in prostate cancer cells
US20110081420A1 (en) * 2009-10-07 2011-04-07 Zyga Technology, Inc. Method of forming prolonged-release injectable steroids
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US20110117175A1 (en) * 2009-11-18 2011-05-19 Rosenbaum Richard J Sweet analgesic for use in medical procedures or treatments
EP2558866B1 (de) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2563776B1 (de) 2010-04-27 2016-06-08 Calcimedica, Inc. Verbindungen als modulatoren von intrazellulärem calcium
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
MX337711B (es) 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
US9066720B2 (en) 2010-10-25 2015-06-30 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP3348220A1 (de) 2012-03-08 2018-07-18 Medtronic Ardian Luxembourg S.à.r.l. Biomarkerprobenahme in zusammenhang mit neuromodulationsvorrichtungen sowie entsprechende systeme
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
AU2014223993B2 (en) 2013-02-28 2016-09-08 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid formulations and its compostions
CN105142625B (zh) 2013-03-15 2019-09-06 儿童医学中心公司 用于长效局部麻醉的新蛤蚌毒素组合配制品
CA2907765C (en) 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
BR112016012728A2 (pt) 2013-12-05 2020-08-11 Pharmacyclics Llc compostos inibidores de tirosina quinase de bruton, composição farmacêutica os compreendendo e uso dos mesmos
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
PT3104853T (pt) 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
HUE049323T2 (hu) 2014-02-10 2020-09-28 Respivant Sciences Gmbh Hízósejt-stabilizálók tüdõbetegség kezelésére
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
US10500303B2 (en) 2014-08-15 2019-12-10 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US10449152B2 (en) * 2014-09-26 2019-10-22 Covidien Lp Drug loaded microspheres for post-operative chronic pain
BR102014028009B1 (pt) 2014-11-10 2023-04-18 Universidade Federal De Pelotas Composições filmogênicas para bioadesivos anestésicos tópicos (bats) para liberação controlada de princípios ativos e bioadesivos anestésicos tópicos
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
US9555155B2 (en) 2014-12-11 2017-01-31 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
EA039121B1 (ru) 2015-02-27 2021-12-07 Куртана Фармасьютикалс, Инк. ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2016191820A1 (en) * 2015-06-02 2016-12-08 Newsouth Innovations Pty Limited Formulation and process for limiting nerve trauma
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (de) 2015-08-07 2018-06-13 Patara Pharma LLC Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren
CA3002515C (en) * 2015-10-23 2024-01-02 Isifer Ab Composition for treatment of infertility in a female subject
CA3003159A1 (en) 2015-10-27 2017-05-04 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
US10117847B2 (en) * 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US11883381B2 (en) 2016-05-12 2024-01-30 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
KR102468670B1 (ko) 2016-08-26 2022-11-17 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
US9943466B1 (en) 2017-05-09 2018-04-17 Research Triangle Institute Biocompatible dental putty formulations for controlled release of bupivacaine
US11452700B2 (en) * 2017-08-04 2022-09-27 Eric Haas Method of delivering an anesthetic agent and glucocorticoid micro and nano bioerodible particles
WO2019071243A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS
EP3706867A4 (de) 2017-11-07 2021-08-11 The Regents Of The University Of Michigan Therapeutische kombination zur behandlung von cerebellärer ataxie
US11110177B2 (en) 2017-11-10 2021-09-07 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
WO2019109065A1 (en) * 2017-12-01 2019-06-06 The Children's Medical Center Corporation Covalent anesthetic-polymer conjugates for prolonged local anesthesia
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
EP3720439A4 (de) 2017-12-07 2021-09-08 The Regents Of The University Of Michigan Inhibitoren der nsd-familie und behandlungsverfahren damit
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
WO2020046466A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
US10925904B2 (en) 2018-11-06 2021-02-23 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
BR112021011578A2 (pt) 2018-12-31 2021-08-31 Biomea Fusion, Llc Inibidores irreversíveis de interação menina-mll
US11833186B2 (en) 2019-02-01 2023-12-05 Myos Corp. Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
EP3937938A1 (de) 2019-03-15 2022-01-19 Unicycive Therapeutics Inc. Nicorandilderivate
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
JP2023533982A (ja) 2020-07-10 2023-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｇａｓ４１阻害剤及びその使用方法
JP6886551B1 (ja) * 2020-11-06 2021-06-16 医療法人祥和会 歯科用の局所麻酔液
CA3202151A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185625A (en) * 1961-11-08 1965-05-25 Brown Ethan Allan Injectionable substances
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
JPS5138412A (en) * 1974-09-24 1976-03-31 Nippon Kayaku Kk Kokoseizai no seiho
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4568535A (en) * 1982-08-06 1986-02-04 Loesche Walter J Composition for periodontal administration
US4946929A (en) * 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4757128A (en) * 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4597960A (en) * 1983-04-19 1986-07-01 Cohen Edgar C Microencapsulated astringent hemostatic agents and methods of use
JPS59222406A (ja) * 1983-06-01 1984-12-14 Teijin Ltd 歯周疾患治療用製剤及びその製造法
US4685883A (en) * 1983-09-12 1987-08-11 Jernberg Gary R Local delivery of chemotherapeutic agents for the treatment of periodontal disease
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4591496A (en) * 1984-01-16 1986-05-27 Massachusetts Institute Of Technology Process for making systems for the controlled release of macromolecules
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4886870A (en) * 1984-05-21 1989-12-12 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4779806A (en) * 1984-07-23 1988-10-25 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4650665A (en) * 1985-02-08 1987-03-17 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4900556A (en) * 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US4806621A (en) * 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US4735945A (en) * 1986-03-13 1988-04-05 Vipont Laboratories, Inc. Method for inhibiting bone resorption and collagenase release
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4919939A (en) * 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
US4933185A (en) * 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US4789724A (en) * 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
JP2816972B2 (ja) * 1987-07-02 1998-10-27 富士写真フイルム株式会社 写真フィルムパトローネ用容器本体
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4933431A (en) * 1987-07-31 1990-06-12 Massachusetts Institute Of Technology One step preparation of poly(amide-anhydride)
US4916204A (en) * 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5122367A (en) * 1989-03-31 1992-06-16 Massachusetts Institute Of Technology Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
DK0528978T3 (da) * 1990-05-16 2003-02-17 Southern Res Inst Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
AU8935591A (en) * 1990-10-30 1992-05-26 Alza Corporation Drug delivery system and method
MX9301817A (es) * 1992-03-30 1994-01-31 Alza Corp Sistema polimerico que contiene un compuesto parcialmente soluble.
PT659073E (pt) * 1992-09-10 2002-06-28 Childrens Medical Center Matrizes polimericas biodegradaveis para entrega sustentada de agentes anestesicos locais
AU5895994A (en) * 1993-10-04 1995-05-01 Mark Chasin Controlled release microspheres

Also Published As

Publication number Publication date
CA2220180A1 (en) 1996-11-07
EP0825853B1 (de) 2004-02-25
EP0825853A1 (de) 1998-03-04
US5700485A (en) 1997-12-23
WO1996034599A1 (en) 1996-11-07
ATE260095T1 (de) 2004-03-15
US6214387B1 (en) 2001-04-10
JPH11504634A (ja) 1999-04-27
AU5720796A (en) 1996-11-21
AU705737B2 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
DE69631654D1 (de) Biodegradierbare polymermatrix mit verzögerter freisetzung von lokalanaesthetika und glucocorticoiden
DK0752245T3 (da) Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler
IE882727L (en) Sustained release pharmaceutical compositions
DE69107773T2 (de) Zusammensetzung zur verlängerter Freigabe und Polymere dafür.
IL111647A0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them
DE69121675D1 (de) Mikrosphäre enthaltende pharmazeutische Zusammensetzung mit kontrollierter Freigabe und Verfahren zur Herstellung
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
ES2180683T3 (es) Preparacion de nifedipina de liberacion con duracion prolongada.
HUT75881A (en) Pharmaceutical composition for 24 hour release of metoprolol
WO1997013502A3 (en) Prolonged release of gm-csf
CA2213560A1 (en) Pharmaceutical compositions for controlled release of soluble receptors
DK0831787T3 (da) Sammensætning til vedvarende frigivelse af humant væksthormon
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
HK1095526A1 (zh) 乳酸聚合物及其製備方法
CA2214895A1 (en) Improved pharmaceutical composition comprising fenofibrate
CA2496441A1 (en) Pharmaceutical compositions of semi-ordered drugs and polymers
ATE442852T1 (de) Trimetazidine enthaltendes arzneimittel mit verzögerter wirkstoffabgabe und verfahren zur herstellung
BG105591A (en) Biodegradable polymer encapsulated serotonin receptor antagonist and method or preparting the same
CA2368348A1 (en) Biodegradable, injectable oligomer-polymer composition
DK287982A (da) Fremgangsmaade til tidsstyring af frigoerelsen af aktive stoffer fra midler med indhold deraf navnlig fra farmaceutiske praeparater
CA2202676A1 (en) Biodegradable polyanhydrides derived from dimers of bile acids, and use thereof as controlled drug release systems
Lim Development of Local Drug Delivery System: Prolonged Sciatic Nerve Blockade From Biodegradable Microspheres
Burrows The Influence of Block Copolymers on Some Properties of Biodegradable Polymer Blends
MX9605929A (es) Formulacion de liberacion sostenida de hormona de crecimiento animal y procedimiento para la preparacion de la misma.

Legal Events

Date Code Title Description
8332 No legal effect for de